Douglas Lane & Associates LLC Buys 4,442 Shares of Illumina, Inc. (NASDAQ:ILMN)

Douglas Lane & Associates LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 1.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 294,787 shares of the life sciences company’s stock after acquiring an additional 4,442 shares during the quarter. Douglas Lane & Associates LLC owned about 0.19% of Illumina worth $39,392,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in ILMN. Versant Capital Management Inc raised its stake in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after purchasing an additional 146 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its position in shares of Illumina by 65.1% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in shares of Illumina during the 2nd quarter worth $61,000. Finally, Private Trust Co. NA grew its holdings in shares of Illumina by 81.2% during the 3rd quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ILMN. Robert W. Baird boosted their target price on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a research report on Wednesday, November 6th. Royal Bank of Canada increased their price objective on shares of Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research note on Thursday, October 17th. UBS Group increased their price target on Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, JPMorgan Chase & Co. boosted their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Eight investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Illumina has an average rating of “Moderate Buy” and an average target price of $165.95.

Illumina Trading Up 0.1 %

Shares of NASDAQ:ILMN traded up $0.12 during midday trading on Wednesday, reaching $139.20. The company’s stock had a trading volume of 643,595 shares, compared to its average volume of 1,260,287. Illumina, Inc. has a fifty-two week low of $100.08 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The firm has a 50 day moving average price of $141.62 and a two-hundred day moving average price of $131.98. The firm has a market capitalization of $22.08 billion, a price-to-earnings ratio of -13.98 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.33 earnings per share. As a group, analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.